Medidata announced that its cloud-based technology platform has been adopted by JCR Pharmaceuticals Co., Ltd.
Medidata announced that its cloud-based technology platform has been adopted by JCR Pharmaceuticals Co., Ltd. The Japanese pioneer in biotherapeutics is leveraging the Medidata Clinical Cloud® to support research on a therapy for the treatment of Fabry disease. With a primary focus on biotherapeutics that use recombinant DNA (rDNA) technology to address significant unmet medical needs, JCR Pharmaceuticals is developing therapeutic enzymes to treat lysosomal storage diseases (including Fabry disease), a group of rare genetic diseases that occur in very small patient populations. For its clinical study on a Fabry disease treatment, JCR Pharmaceuticals has selected Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®).
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.